CN1976928A - 作为5－羟基色胺－6配体的吲哚基烷基胺代谢物 - Google Patents

作为5－羟基色胺－6配体的吲哚基烷基胺代谢物 Download PDF

Info

Publication number
CN1976928A
CN1976928A CNA2005800206836A CN200580020683A CN1976928A CN 1976928 A CN1976928 A CN 1976928A CN A2005800206836 A CNA2005800206836 A CN A2005800206836A CN 200580020683 A CN200580020683 A CN 200580020683A CN 1976928 A CN1976928 A CN 1976928A
Authority
CN
China
Prior art keywords
compound
alkyl
circumstances
indol
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800206836A
Other languages
English (en)
Chinese (zh)
Inventor
王友初
贾-成·肖
罗纳德·查尔斯·别尔诺塔斯
仲－奇·保罗·王
蔡平
王智
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35033547&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1976928(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Publication of CN1976928A publication Critical patent/CN1976928A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/033—Uronic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA2005800206836A 2004-06-23 2005-06-21 作为5－羟基色胺－6配体的吲哚基烷基胺代谢物 Pending CN1976928A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58229004P 2004-06-23 2004-06-23
US60/582,290 2004-06-23

Publications (1)

Publication Number Publication Date
CN1976928A true CN1976928A (zh) 2007-06-06

Family

ID=35033547

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800206836A Pending CN1976928A (zh) 2004-06-23 2005-06-21 作为5－羟基色胺－6配体的吲哚基烷基胺代谢物

Country Status (19)

Country Link
US (1) US7498327B2 (cg-RX-API-DMAC7.html)
EP (1) EP1758898A1 (cg-RX-API-DMAC7.html)
JP (1) JP2008504267A (cg-RX-API-DMAC7.html)
KR (1) KR20070041514A (cg-RX-API-DMAC7.html)
CN (1) CN1976928A (cg-RX-API-DMAC7.html)
AR (1) AR049449A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005258025A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0512540A (cg-RX-API-DMAC7.html)
CA (1) CA2570818A1 (cg-RX-API-DMAC7.html)
CR (1) CR8825A (cg-RX-API-DMAC7.html)
EC (1) ECSP067096A (cg-RX-API-DMAC7.html)
IL (1) IL180198A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007000182A (cg-RX-API-DMAC7.html)
NO (1) NO20070065L (cg-RX-API-DMAC7.html)
PA (1) PA8637801A1 (cg-RX-API-DMAC7.html)
PE (1) PE20060303A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006146923A (cg-RX-API-DMAC7.html)
TW (1) TW200606148A (cg-RX-API-DMAC7.html)
WO (1) WO2006002125A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9101613B2 (en) 2006-02-15 2015-08-11 Neurim Pharmaceuticals (1991) Ltd. Methods for treating neurological disease
US7635710B2 (en) * 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
EP1953153A1 (en) * 2007-01-31 2008-08-06 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted sulfonamides for the treatment of cognitive or food ingestion related disorders
EP2053052A1 (en) 2007-10-23 2009-04-29 Laboratorios del Dr. Esteve S.A. Process for the preparation of 6-substituted imidazo[2,1-b]thiazole-5-sulfonyl halide
EP3083588B1 (en) 2013-12-20 2020-12-09 Sunshine Lake Pharma Co., Ltd. Aromatic heterocyclic compounds and their application in pharmaceuticals

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3489767A (en) * 1966-01-12 1970-01-13 Sumitomo Chemical Co 1-(phenylsulfonyl)-3-indolyl aliphatic acid derivatives
GB9820113D0 (en) * 1998-09-15 1998-11-11 Merck Sharp & Dohme Therapeutic agents
US6380166B1 (en) * 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
DE60213856T2 (de) * 2001-12-20 2007-09-13 Wyeth Indolylalkylamin-derivate als 5-hydroxytryptamin-6 liganden
US20060089353A1 (en) * 2003-03-06 2006-04-27 Maki Iwahashi Indole derivative compounds and drugs containing the compounds as the active ingredient
KR20130023381A (ko) * 2003-07-17 2013-03-07 플렉시콘, 인코퍼레이티드 Ｐｐａｒ 활성 화합물
WO2005040112A1 (en) * 2003-10-14 2005-05-06 Oxagen Limited Compounds with pgd2 antagonist activity

Also Published As

Publication number Publication date
RU2006146923A (ru) 2008-07-27
PE20060303A1 (es) 2006-05-19
NO20070065L (no) 2007-01-04
US20060003945A1 (en) 2006-01-05
PA8637801A1 (es) 2006-06-02
AR049449A1 (es) 2006-08-02
AU2005258025A1 (en) 2006-01-05
EP1758898A1 (en) 2007-03-07
BRPI0512540A (pt) 2008-03-25
US7498327B2 (en) 2009-03-03
CA2570818A1 (en) 2006-01-05
WO2006002125A1 (en) 2006-01-05
CR8825A (es) 2007-08-28
IL180198A0 (en) 2007-06-03
JP2008504267A (ja) 2008-02-14
ECSP067096A (es) 2007-02-28
MX2007000182A (es) 2007-03-23
KR20070041514A (ko) 2007-04-18
TW200606148A (en) 2006-02-16

Similar Documents

Publication Publication Date Title
CN1048985C (zh) 作为5－ht1a拮抗剂的哌嗪衍生物
CN1066727C (zh) 抗周期性偏头痛的吲哚衍生物盐
EP2069342B1 (fr) Derives de 2-aryl-6-phenyl-imidazo[1,2-a]pyridines, leur preparation et leur application en therapeutique
CN1065535C (zh) 用于治疗神经及其它疾病的吡唑并嘧啶和吡咯并嘧啶
CN1330652A (zh) 用作5HT2C激动剂的2,3,4,4a－四氢－1H－吡嗪并(1,2－a)喹喔啉－5(6H)酮衍生物
TW202216705A (zh) 取代哌啶化合物及其用途
CN86105400A (zh) 茶醚
CN101909628A (zh) 作为白三烯a4水解酶调节剂的芳基取代的桥接或稠合二胺
JP2012530682A (ja) （２ｓ）−（−）−ｎ−（６−クロロ−２，３−ジヒドロ−ベンゾ［１，４］ジオキシン−２−イルメチル）−スルファミドの結晶形態
CN102159563A (zh) 新的取代的磺酰胺衍生物
CN1032309C (zh) 吲哚衍生物
HUE033583T2 (hu) Új indánszulfamid származékok
CN117534631B (zh) 一种苯基噻唑胺类PI4KIIIβ抑制剂、制法及其药物组合物和应用
FR2928149A1 (fr) Composes derives d'azetidines, leur preparation et leur application en therapeutique
BR112019018688A2 (pt) derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2
AU2019306532A1 (en) Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis
CN1336369A (zh) 苯并吡喃类化合物和它们作为治疗剂的用途
JP2012509861A (ja) 皮質のカテコールアミン作動性神経伝達のモジュレーターとしての３−フェニル−３−メトキシピロリジン誘導体
CN1976928A (zh) 作为5－羟基色胺－6配体的吲哚基烷基胺代谢物
CN1878756A (zh) 作为5－羟色胺－6配体的磺酰基四氢－3h－苯并(e)吲哚－8－胺化合物
RU2334742C2 (ru) Производные бензоксазола и фармацевтическая композиция, обладающая свойствами лигандов рецептора аденозина
JP4675938B2 (ja) 新規ナフタレン化合物、その製造法、およびそれを含有する薬学的組成物
JP5621087B2 (ja) 皮質のカテコールアミン作動性神経伝達のモジュレーターとして有用な新規な３−フェニル−アゼチジン誘導体
CN1168728C (zh) 吡咯并异喹啉和四氢吡咯并异喹衍生物及其作为5-ht7受体介体的应用
JP2008013558A (ja) 新規ナフタレン化合物、その製造法、およびそれを含有する薬学的組成物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20070606